- Home
- PC vs KZIA Comparison
PC vs KZIA Comparison
Compare PC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- KZIA
- Stock Information
- Founded
- PC 2012
- KZIA 1994
- Country
- PC Singapore
- KZIA Australia
- Employees
- PC N/A
- KZIA N/A
- Industry
- PC Restaurants
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- KZIA Health Care
- Exchange
- PC Nasdaq
- KZIA Nasdaq
- Market Cap
- PC 11.1M
- KZIA 12.6M
- IPO Year
- PC 2024
- KZIA 1999
- Fundamental
- Price
- PC $0.73
- KZIA $4.57
- Analyst Decision
- PC
- KZIA Strong Buy
- Analyst Count
- PC 0
- KZIA 1
- Target Price
- PC N/A
- KZIA $20.00
- AVG Volume (30 Days)
- PC 846.1K
- KZIA 139.2K
- Earning Date
- PC 11-26-2024
- KZIA 11-29-2024
- Dividend Yield
- PC N/A
- KZIA N/A
- EPS Growth
- PC N/A
- KZIA N/A
- EPS
- PC N/A
- KZIA N/A
- Revenue
- PC $3,809,288.00
- KZIA $1,663,331.00
- Revenue This Year
- PC N/A
- KZIA $4,053,954.00
- Revenue Next Year
- PC N/A
- KZIA N/A
- P/E Ratio
- PC N/A
- KZIA N/A
- Revenue Growth
- PC N/A
- KZIA 10739.13
- 52 Week Low
- PC $0.60
- KZIA $1.90
- 52 Week High
- PC $5.73
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PC N/A
- KZIA 43.58
- Support Level
- PC N/A
- KZIA $5.63
- Resistance Level
- PC N/A
- KZIA $6.88
- Average True Range (ATR)
- PC 0.00
- KZIA 0.83
- MACD
- PC 0.00
- KZIA -0.16
- Stochastic Oscillator
- PC 0.00
- KZIA 7.69
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. They specialize in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.